cbdMD, Inc.

What they do

cbdMD produces and markets a broad line of domestically produced CBD products (THC-free) and Farm Bill-compliant Delta-9 offerings, along with hemp-derived THC seltzers under the Herbal Oasis brand, veterinarian-formulated pet products under Paw CBD, and natural functional mushroom support under ATRx. The company sells through its own websites, thousands of retail outlets, and direct-to-consumer channels.

Revenue drivers

• cbdMD branded products — Core CBD line (oils, gummies, topicals) sold via cbdmd.com and retail; represents the bulk of revenue.
• Herbal Oasis seltzers — Premium hemp-derived THC seltzers, a newer product line targeting beverage consumers.
• Paw CBD pet products — Veterinarian-formulated CBD pet products sold through pawcbd.com and retail, a distinct brand line.
• ATRx mushroom supplements — Natural functional mushroom support products, a smaller brand line in the portfolio.

Recent performance

Fiscal 2025 net sales were $19.2M, essentially flat versus $19.5M in fiscal 2024, with net loss improving to $2.0M from $3.7M. Quarterly revenue has sequentially increased each quarter of fiscal 2026: $4.7M (Sep-2025), $5.0M (Dec-2025), $5.6M (Mar-2026), $5.6M (Jun-2026). The company reported a net loss of $1.5M in operating cash flow for fiscal 2025. Cash and equivalents were $2.1M at June 30, 2026, with total assets of $13.1M and total liabilities of $4.9M.

Strategy

Management has focused on disciplined cost management, improving profitability, and stabilizing revenue. They highlight 'positive sequential and year-over-year revenue growth' in fiscal Q4 2025 and claim to outperform public peers who reported 8-10% declines. The company continues to expand its product portfolio, including herbal seltzers and functional mushrooms, and relies on its multi-brand, direct-to-consumer plus retail distribution model. Recent 8-K filings indicate new material agreements, equity sales, and charter/bylaw amendments, suggesting ongoing capital management and partnership activity.

Risks

• Regulatory uncertainty — CBD and Delta-9 products face evolving federal and state regulation, which could restrict marketing or sales.
• Cash constraints — With only $2.1M cash and ongoing net losses, the company may need additional capital to fund operations.
• Competitive pressure — The CBD market is crowded with many brands, and the company acknowledges public peers experiencing sales declines.
• Dependence on retail relationships — Retail distribution is important; losing key retail partners could materially impact revenue.

Outlook

Management expects continued earnings improvement and a multi-year track record of improving the business. They express confidence in navigating the complex regulatory environment and building on momentum across brands. The company is focused on durable long-term growth, though specific fiscal 2026 guidance was not provided in the available excerpts.